



THE DRIVE YOU DEMAND

For Qualified Investors in Switzerland, or Professional Investors or Eligible Counterparties as defined by the relevant laws

U ACCESS (IRL) NEXThERA UCITS

Access to a liquid and regulated vehicle of a leading long/short healthcare specialist

Key points



- ◆ Longshort equity strategy focusing on the global healthcare sector with an emphasis on therapeutics, pharmaceuticals, and biotech
- ◆ Deep fundamental research based on thorough scientific and financial analysis
- ◆ Convex return profile vs. equities
- ◆ Portfolio manager with 20 years of experience in the sector
- ◆ UCITS with weekly liquidity

Investment case: bringing comfort to equity investors through sector expertise

- ◆ Although equities bring value to a portfolio in the long run, they are characterised by an embedded risk of short-term volatility and severe drawdowns.
- ◆ The current “risk on/risk off” market regime is expected to last, with potential catalysts for increased volatility including geopolitical concerns, commercial tensions, challenges faced by the Trump administration in achieving its programme, and increased correlation between bond and equity returns.
- ◆ In this context, an increasing number of equity investors are looking for protection and comfort, and there is a strong need for alternative strategies providing smoothed-volatility investment solutions and showing a convex profile vs. long-only equities, with the ultimate objective of reducing the overall risk of a global portfolio through controlled participation in the markets (beta).
- ◆ We strongly believe that one efficient way to cope with this market environment is to favour very active alternative managers with proven expertise in select sectors.
- ◆ U Access (IRL) NEXThERA UCITS belongs to that category of active long/short managers. The fund aims to seize long and short investment opportunities within healthcare, a sector characterised by tremendous structural changes that can impact stocks up or down.

Sector focus: why healthcare now?

- ◆ Time of strong innovation. 2018 is a catalyst-rich year with late-phase data from cutting-edge technologies that have been maturing over the past decade
 - ▶ Immuno-oncology
 - ▶ Gene therapy and editing
 - ▶ CAR-T therapies
 - ▶ RNAi
- ◆ Time of broad M&A activity
 - ▶ Large caps have high demand for innovative assets
 - ▶ And they have deep pockets from cash repatriation
- ◆ Time of regulatory leniency
 - ▶ The FDA is approving more drugs
- ◆ Idiosyncratic factors create winners and losers. As a result, healthcare exhibits a high dispersion of returns, making long/short expertise necessary for investing in this sector



UNION BANCAIRE PRIVÉE

Source: UBP
Past performance is not indicative of future results

Investment process

- ◆ Focuses on the global healthcare sector with an emphasis on therapeutics (i.e. large-cap pharma, generics, specialty pharma and biotech)
- ◆ Identifies investment opportunities (both long and short) across market capitalisations and geographies based on thorough scientific and financial analysis.
- ◆ Invested in 35 to 50 positions, all listed stocks. Risk controls through active exposure management and strict position limits
- ◆ Relies on deep fundamental research and extensive network
- ◆ Seeks to achieve high, risk-adjusted returns with limited correlation to equity markets and the sector

Investment guidelines

- ◆ Number of stocks: 35–50
- ◆ Gross exposure range: 100–150%
- ◆ Net exposure range: 20–80%
- ◆ Market cap concentration (avg): Large 60%, Mid 30%
- ◆ Regional concentration (avg): US 40%, EU 40%, RoW 20%
- ◆ Liquidity: 100% in 1–5 days
- ◆ Volatility budget: 10% (on average)

Investment team – Nextthera Capital

- ◆ Investment team led by Rael Mazansky, CIO and partner. Extensive experience in running healthcare and biopharma books in various firms (e.g. Surveyor Capital (Citadel) and Kallex Capital)
- ◆ 3 additional investment professionals, including 2 MDs
- ◆ Strong, global network with industry stakeholders
- ◆ Risk-management focused
- ◆ Proven track record, having successfully navigated various, challenging environments

General information (Clean share class B)

Fund name	U Access (IRL) NEXTHERA UCITS
Legal structure	Irish UCITS
Launch date	July 2017
Valuation day	Weekly (Wednesday = D)
Subscription terms	Cut-off: D - 2BD; Settlement: D
Redemption terms	Cut-off: D - 2BD; Settlement: D + 4BD
Fee structure	1.50% management fee and 20% performance fee
Minimum subscriptions	None

Disclaimer

This is a marketing document and is intended for informational and/or marketing purposes only. It is confidential and is intended to be used only by the person(s) to whom it was delivered. It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible, to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group ("UBP"). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Qualified Investors in Switzerland or Professional Clients, Eligible Counterparties or an equivalent category of investors as defined by the relevant laws (all such persons together being referred to as "relevant persons"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed to any person to whom or entity to which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP's financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. Past performance is not a guide to current or future results. The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors' returns. All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements do not guarantee future performances. The financial projections included in this document do not represent forecasts or budgets, but are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. The contents of this document should not be construed as any form of advice or recommendation to purchase or sell any security or funds. This document does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of a fund or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make his/her own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and are advised to seek professional counsel from financial, legal and tax specialists. The tax treatment of any investment depends on the investor's individual circumstances and may be subject to change in the future. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. The Swiss representative is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen. The Swiss paying agent is Bank Vontobel SA, Gotthardstrasse 43, CH-8002 Zurich. The prospectus, articles of association, KIIDs, and annual and semi-annual reports may be obtained free of charge from UBP as well as from the Swiss representative. Telephone calls to the telephone number stated in this presentation may be recorded. UBP will assume that, by calling this number, you consent to this recording. In Switzerland, UBP is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA); in the United Kingdom, it is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority (FCA).

Union Bancaire Privée, UBP SA

Rue du Rhône 96-98 | P.O. box 1320 | 1211 Geneva 1 | Switzerland | ubp@ubp.com | www.ubp.com

Portfolio construction

Short large cap

- ▶ Patent expirations with looming generic entrants
- ▶ Pricing pressure
- ▶ Uninspiring pipelines
- ▶ High valuations
- ▶ Threats of new wave of innovative competition

Illustrative companies for category*



Long de-risked biotech

- ▶ Post Phase 3, clinically de-risked assets
- ▶ On the brink of commercialisation and consensus underestimates the market opportunity
- ▶ Attractive M&A targets

Illustrative companies for category*



Long high science biotech

- ▶ Mid- to late-stage pipeline products
- ▶ High conviction on the science and probability of clinical success
- ▶ Trading far below risk-adjusted potential

Illustrative companies for category*



Long cheap value

- ▶ Recent share price constriction
- ▶ Value trade, with stable revenue generation
- ▶ Strong fundamental value drivers and SOTP on worst scenario is higher than market

Illustrative companies for category*



*Not necessarily in the Nextthera portfolio

Main risks



SRRI relates to the I USD share class IE00BF2MLZ04 as of 31.01.2019. This indicator represents the annual historical volatility of the fund. Risk category reflects level of risk and return profile: 1 lowest; 2 low; 3 limited; 4 average/moderate; 5 high; 6 very high; 7 highest risk. Historical data such as that used to calculate the synthetic indicator cannot be considered as a reliable indication of the fund's future risk profile. The risk category associated with the fund is not guaranteed and may change over time.